News

Preclinical trials show Alzheimer's drug promising for alcohol addiction treatment
A research team from Virginia Commonwealth University has found that a drug currently in clinical trials for brain disorders ...
Johnson & Johnson: Supplemental new drug application submitted to U.S. FDA for CAPLYTA (lumateperone) with data demonstrating significant schizophrenia relapse prevention ...
Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA® is FDA ...
ALS News Today55m
Klotho advances ALS gene therapy KLTO‑202 to manufacturing phase
Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...